person · Reporting owner

Bauer Jake

Disclosed activity across 6 companies

Tapewire entity: 36849
SEC CIK: 0001654909

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARYA Sciences Acquisition Corp VARYE · Entity 137308	Director	July 12, 2021	July 12, 2021
BridgeBio Oncology Therapeutics, Inc.BBOT · Entity 5215	Director	June 16, 2026	June 18, 2026
Cerevel Therapeutics Holdings, Inc.ARYB · Entity 15182	Director	June 04, 2020	June 04, 2020
Enliven Therapeutics, Inc.ELVN · Entity 4024	Director	February 12, 2026	February 18, 2026
Immunovant, Inc.IMVT · Entity 3632	Director	April 07, 2026	April 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARYA Sciences Acquisition Corp V

Report date July 12, 2021 · Filed July 12, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B ordinary sharesSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2021-07-12 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-257335) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-257335) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.

BridgeBio Oncology Therapeutics, Inc.

Report date June 16, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.73 · Expires 2036-06-15	Direct	31,675	Reported balance After 2026-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-16 · Grant · Acquired 31,675 · Balance 31,675 F1: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Cerevel Therapeutics Holdings, Inc.

Report date June 04, 2020 · Filed June 04, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B ordinary sharesSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2020-06-04 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-238488) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-238488) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.

Enliven Therapeutics, Inc.

Report date February 12, 2026 · Filed February 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.16 · Expires 2036-02-12	Direct	17,126	Reported balance After 2026-02-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-12 · Grant · Acquired 17,126 · Balance 17,126 F1: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date.

Immunovant, Inc.

Report date April 07, 2026 · Filed April 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	38,896	Reported balance After 2026-04-07 transaction · row 1 1 source row Row 1 · 2026-04-07 · Grant · Acquired 13,880 · Balance 38,896 F1: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.61 · Expires 2036-04-07	Direct	7,061	Reported balance After 2026-04-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-07 · Grant · Acquired 7,061 · Balance 7,061 F2: These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date.

Filing footnotes · ownership attribution and instrument terms

F1: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

F2: These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MyoKardia, Inc.

Report date November 17, 2020 · Filed November 19, 2020

Section 16 reporting ended · disclosed 2020-11-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-11-17 transaction · row 1 1 source row Row 1 · 2020-11-17 · Other · Disposed 90,209 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price. F3: Includes 134 Shares acquired under the Issuer's Employee Stock Purchase Plan on October 31, 2020 in a transaction exempt under Rule 16b-3.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.51	Direct	Reported balance After 2020-11-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-11-17 · Disposition to issuer · Disposed 16,530 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08	Direct	Reported balance After 2020-11-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-17 · Disposition to issuer · Disposed 8,748 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.25	Direct	Reported balance After 2020-11-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-17 · Disposition to issuer · Disposed 35,150 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.11	Direct	Reported balance After 2020-11-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-11-17 · Disposition to issuer · Disposed 57,400 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.00	Direct	Reported balance After 2020-11-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-11-17 · Disposition to issuer · Disposed 34,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.40	Direct	Reported balance After 2020-11-17 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-11-17 · Disposition to issuer · Disposed 45,193 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.

F3: Includes 134 Shares acquired under the Issuer's Employee Stock Purchase Plan on October 31, 2020 in a transaction exempt under Rule 16b-3.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 16, 2026 Filed Jun 18, 2026 20:54 UTC	BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215	GrantStock Option (Right to Buy) · Derivative	31,675	$0.00 Strike: $7.73	$0.00	Disclosure SEC source: 0001193125-26-276035 · ownership.xml · derivative · entry 1 Bauer Jake · CIK 0001654909 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,675 Underlying: Common Stock · 31,675 shares Expires 2036-06-15 F1 · derivative.exercise_date: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document
April 07, 2026 Filed Apr 9, 2026 20:23 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantStock Option (right to buy) · Derivative	7,061	$0.00 Strike: $24.61	$0.00	Disclosure SEC source: 0001764013-26-000044 · wk-form4_1775766231.xml · derivative · entry 2 Bauer Jake · CIK 0001654909 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,061 Underlying: Common Stock · 7,061 shares Expires 2036-04-07 F2 · derivative.exercise_date: These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document
April 07, 2026 Filed Apr 9, 2026 20:23 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantCommon Stock	13,880	$0.00	$0.00	Disclosure SEC source: 0001764013-26-000044 · wk-form4_1775766231.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,896 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document
February 12, 2026 Filed Feb 18, 2026 00:56 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	GrantStock Option (right to buy) · Derivative	17,126	$0.00 Strike: $27.16	$0.00	Disclosure SEC source: 0001654909-26-000001 · form4-02182026_120203.xml · derivative · entry 1 Bauer Jake · CIK 0001654909 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,126 Underlying: Common Stock · 17,126 shares Expires 2036-02-12 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date. Read SEC document
August 26, 2025 Filed Aug 28, 2025 20:41 UTC	BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215	GrantStock Option (Right to Buy) · Derivative	138,193	$0.00 Strike: $9.59	$0.00	Disclosure SEC source: 0000950170-25-112008 · ownership.xml · derivative · entry 1 Bauer Jake · CIK 0001654909 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,193 Underlying: Common Stock · 138,193 shares Expires 2035-08-25 F1 · derivative.exercise_date: A fraction of the shares underlying such option equal to (x) the number of full months between April 25, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date. Read SEC document
May 01, 2025 Filed May 5, 2025 23:30 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantStock Option (Right to Buy) · Derivative	35,234	$0.00 Strike: $15.90	$0.00	Disclosure SEC source: 0001415889-25-012046 · form4-05052025_070503.xml · derivative · entry 2 Bauer Jake · CIK 0001654909 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,234 Underlying: Common Stock · 35,234 shares Expires 2035-05-01 F2 · derivative.exercise_date: These options were granted pursuant to the Plan. The shares underlying the options will vest in three equal annual installments beginning on May 1, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document
May 01, 2025 Filed May 5, 2025 23:30 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantCommon Stock	25,016	$0.00	$0.00	Disclosure SEC source: 0001415889-25-012046 · form4-05052025_070503.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,016 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in three equal annual installments beginning on May 1, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document
February 06, 2025 Filed Feb 10, 2025 22:34 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	GrantStock Option (right to buy) · Derivative	20,491	$0.00 Strike: $22.47	$0.00	Disclosure SEC source: 0001415889-25-003517 · form4-02102025_100225.xml · derivative · entry 1 Bauer Jake · CIK 0001654909 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,491 Underlying: Common Stock · 20,491 shares Expires 2035-02-06 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2025 annual meeting of the Issuer's stockholders or (ii) the date of the 2026 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date. Read SEC document
February 13, 2024 Filed Feb 16, 2024 01:44 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	GrantStock Option (right to buy) · Derivative	16,835	$0.00 Strike: $14.85	$0.00	Disclosure SEC source: 0001415889-24-004010 · form4-02162024_010212.xml · derivative · entry 1 Bauer Jake · CIK 0001654909 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,835 Underlying: Common Stock · 16,835 shares Expires 2034-02-12 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date. Read SEC document
February 13, 2024 Filed Feb 21, 2024 00:26 UTC Amendment	Enliven Therapeutics, Inc. ELVN · Entity 4024	GrantStock Option (right to buy) · Derivative	23,364	$0.00 Strike: $14.85	$0.00	Disclosure SEC source: 0001415889-24-004484 · form4a-02212024_120202.xml · derivative · entry 1 Bauer Jake · CIK 0001654909 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,364 Underlying: Common Stock · 23,364 shares Expires 2034-02-13 F1 · shares: The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant. F2 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date. F1 · derivative.underlying_shares: The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant. F1 · balance_after: The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant. Read SEC document
February 23, 2023 Filed Feb 28, 2023 02:51 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	GrantStock Option · Derivative	17,706	$0.00 Strike: $2.48	$0.00	Disclosure SEC source: 0001209191-23-013515 · doc4.xml · derivative · entry 2 Bauer Jake · CIK 0001654909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,706 Underlying: Common Stock · 17,706 shares Expires 2032-08-12 F2 · derivative.exercise_date: Shares subject to the option vest in 24 equal monthly installments beginning on September 24, 2022. Read SEC document
February 23, 2023 Filed Feb 28, 2023 02:51 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	GrantCommon Stock	87,372	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-013515 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,372 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of the Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN." Read SEC document
February 23, 2023 Filed Apr 7, 2023 00:16 UTC	Enliven Therapeutics, Inc. ELVN · Entity 4024	GrantStock Option (right to buy) · Derivative	27,567	$0.00 Strike: $25.28	$0.00	Disclosure SEC source: 0001209191-23-023662 · doc4.xml · derivative · entry 1 Bauer Jake · CIK 0001654909 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,567 Underlying: Common Stock · 27,567 shares Expires 2033-02-23 F1 · derivative.exercise_date: 1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
November 17, 2020 Filed Nov 19, 2020 20:19 UTC	MyoKardia, Inc. MYOK · Entity 145206	Disposition to issuerStock Option (Right to buy) · Derivative	45,193	Not disclosed Strike: $70.40	Not disclosed	Disclosure SEC source: 0000899243-20-031756 · doc4.xml · derivative · entry 7 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,193 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document
November 17, 2020 Filed Nov 19, 2020 20:19 UTC	MyoKardia, Inc. MYOK · Entity 145206	Disposition to issuerStock Option (Right to buy) · Derivative	34,000	Not disclosed Strike: $52.00	Not disclosed	Disclosure SEC source: 0000899243-20-031756 · doc4.xml · derivative · entry 6 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document
November 17, 2020 Filed Nov 19, 2020 20:19 UTC	MyoKardia, Inc. MYOK · Entity 145206	Disposition to issuerStock Option (Right to buy) · Derivative	57,400	Not disclosed Strike: $40.11	Not disclosed	Disclosure SEC source: 0000899243-20-031756 · doc4.xml · derivative · entry 5 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,400 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document
November 17, 2020 Filed Nov 19, 2020 20:19 UTC	MyoKardia, Inc. MYOK · Entity 145206	Disposition to issuerStock Option (Right to buy) · Derivative	35,150	Not disclosed Strike: $12.25	Not disclosed	Disclosure SEC source: 0000899243-20-031756 · doc4.xml · derivative · entry 4 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,150 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document
November 17, 2020 Filed Nov 19, 2020 20:19 UTC	MyoKardia, Inc. MYOK · Entity 145206	Disposition to issuerStock Option (Right to buy) · Derivative	8,748	Not disclosed Strike: $9.08	Not disclosed	Disclosure SEC source: 0000899243-20-031756 · doc4.xml · derivative · entry 3 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,748 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document
November 17, 2020 Filed Nov 19, 2020 20:19 UTC	MyoKardia, Inc. MYOK · Entity 145206	Disposition to issuerStock Option (Right to buy) · Derivative	16,530	Not disclosed Strike: $1.51	Not disclosed	Disclosure SEC source: 0000899243-20-031756 · doc4.xml · derivative · entry 2 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,530 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document
November 17, 2020 Filed Nov 19, 2020 20:19 UTC	MyoKardia, Inc. MYOK · Entity 145206	OtherCommon Stock	90,209	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-031756 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2 · shares: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price. F3 · shares: Includes 134 Shares acquired under the Issuer's Employee Stock Purchase Plan on October 31, 2020 in a transaction exempt under Rule 16b-3. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2 · price: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price. Read SEC document
April 30, 2020 Filed Jun 4, 2020 16:20 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantCommon Stock	293	$50.41	$14,771.16	Disclosure SEC source: 0000899243-20-015248 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,784 F1 · kind: Shares acquired pursuant to the Issuer's 2013 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c). Read SEC document
February 14, 2020 Filed Feb 19, 2020 20:40 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantRestricted Stock Units · Derivative	14,591	$0.00	$0.00	Disclosure SEC source: 0000899243-20-005184 · doc4.xml · derivative · entry 2 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,591 Underlying: Common Stock · 14,591 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document
February 14, 2020 Filed Feb 19, 2020 20:40 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantStock Option (Right to Buy) · Derivative	45,193	$0.00 Strike: $70.40	$0.00	Disclosure SEC source: 0000899243-20-005184 · doc4.xml · derivative · entry 1 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,193 Underlying: Common Stock · 45,193 shares Expires 2030-02-13 F1 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments from January 1, 2020, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document
January 06, 2020 Filed Jan 7, 2020 17:15 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	2,466	$68.45	$168,800.41	Disclosure SEC source: 0000899243-20-000730 · doc4.xml · nonDerivative · entry 2 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,491 F1 · kind: Shares sold to cover withholding taxes in connection with vesting of Restricted Stock Units reported on Form 4 filed by the Reporting Person on January 3, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $68.35 to $68.66 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 03, 2020 Filed Jan 7, 2020 17:15 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $1.51	$0.00	Disclosure SEC source: 0000899243-20-000730 · doc4.xml · derivative · entry 3 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,326 Underlying: Common Stock · 10,000 shares Expires 2025-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on June 4, 2016, and the remainder vested and became exercisable in 36 equal monthly installments thereafter. Read SEC document
January 03, 2020 Filed Jan 7, 2020 17:15 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionCommon Stock	10,000	$1.51	$15,100.00	Disclosure SEC source: 0000899243-20-000730 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 01, 2020 Filed Jan 3, 2020 20:15 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionRestricted Stock Units · Derivative	4,950	$0.00	$0.00	Disclosure SEC source: 0000899243-20-000382 · doc4.xml · derivative · entry 3 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,850 Underlying: Common Stock · 4,950 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document
January 01, 2020 Filed Jan 3, 2020 20:15 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionRestricted Stock Units · Derivative	1,425	$0.00	$0.00	Disclosure SEC source: 0000899243-20-000382 · doc4.xml · derivative · entry 2 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,850 Underlying: Common Stock · 1,425 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document
January 01, 2020 Filed Jan 3, 2020 20:15 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionCommon Stock	6,375	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-000382 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
December 20, 2019 Filed Dec 23, 2019 21:07 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $13.90	$0.00	Disclosure SEC source: 0000899243-19-030015 · doc4.xml · derivative · entry 5 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. F4 · derivative.exercise_date: The shares subject to this option vested in two annual installments after July 20, 2017. Read SEC document
December 20, 2019 Filed Dec 23, 2019 21:07 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $9.08	$0.00	Disclosure SEC source: 0000899243-19-030015 · doc4.xml · derivative · entry 4 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,748 Underlying: Common Stock · 10,000 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. F3 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments from January 1, 2016, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
December 20, 2019 Filed Dec 23, 2019 21:07 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	18,916	$70.07	$1,325,421.42	Disclosure SEC source: 0000899243-19-030015 · doc4.xml · nonDerivative · entry 3 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,582 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $70.00 to $70.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
December 20, 2019 Filed Dec 23, 2019 21:07 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionCommon Stock	7,500	$13.90	$104,250.00	Disclosure SEC source: 0000899243-19-030015 · doc4.xml · nonDerivative · entry 2 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. Read SEC document
December 20, 2019 Filed Dec 23, 2019 21:07 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionCommon Stock	10,000	$9.08	$90,800.00	Disclosure SEC source: 0000899243-19-030015 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. Read SEC document
November 29, 2019 Filed Dec 2, 2019 16:10 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	800	$66.32	$53,056.00	Disclosure SEC source: 0000899243-19-028345 · doc4.xml · nonDerivative · entry 3 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,998 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. F4 · price: Represents the weighted average sale price of the shares sold ranging from $66.04 to $66.44 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
November 29, 2019 Filed Dec 2, 2019 16:10 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	7,336	$65.52	$480,654.72	Disclosure SEC source: 0000899243-19-028345 · doc4.xml · nonDerivative · entry 2 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,798 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $65.00 to $65.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
November 27, 2019 Filed Dec 2, 2019 16:10 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	13,096	$65.13	$852,976.53	Disclosure SEC source: 0000899243-19-028345 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,134 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $65.00 to $65.44 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
October 31, 2019 Filed Nov 8, 2019 19:51 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantCommon Stock	162	$40.07	$6,491.18	Disclosure SEC source: 0000899243-19-027044 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,230 F1 · kind: Shares acquired pursuant to the Issuer's 2013 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c). Read SEC document
September 20, 2019 Filed Sep 24, 2019 16:05 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionStock Option (Right to Buy) · Derivative	9,700	$0.00 Strike: $12.25	$0.00	Disclosure SEC source: 0000899243-19-024147 · doc4.xml · derivative · entry 5 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,150 Underlying: Common Stock · 9,700 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. F4 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments from January 1, 2017, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
September 20, 2019 Filed Sep 24, 2019 16:05 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $9.08	$0.00	Disclosure SEC source: 0000899243-19-024147 · doc4.xml · derivative · entry 4 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,748 Underlying: Common Stock · 10,000 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. F3 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments from January 1, 2016, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
September 20, 2019 Filed Sep 24, 2019 16:05 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	19,700	$60.09	$1,183,776.94	Disclosure SEC source: 0000899243-19-024147 · doc4.xml · nonDerivative · entry 3 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,068 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $60.00 to $60.27 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
September 20, 2019 Filed Sep 24, 2019 16:05 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionCommon Stock	9,700	$12.25	$118,825.00	Disclosure SEC source: 0000899243-19-024147 · doc4.xml · nonDerivative · entry 2 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. Read SEC document
September 20, 2019 Filed Sep 24, 2019 16:05 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionCommon Stock	10,000	$9.08	$90,800.00	Disclosure SEC source: 0000899243-19-024147 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. Read SEC document
April 30, 2019 Filed Jun 3, 2019 17:48 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantCommon Stock	313	$40.78	$12,765.08	Disclosure SEC source: 0000899243-19-015396 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,068 F1 · kind: Shares acquired pursuant to the Issuer's 2013 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c). Read SEC document
February 08, 2019 Filed Feb 12, 2019 16:20 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantRestricted Stock Units · Derivative	19,800	$0.00	$0.00	Disclosure SEC source: 0000899243-19-003277 · doc4.xml · derivative · entry 2 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,800 Underlying: Common Stock · 19,800 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document
February 08, 2019 Filed Feb 12, 2019 16:20 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantStock Option (Right to Buy) · Derivative	57,400	$0.00 Strike: $40.11	$0.00	Disclosure SEC source: 0000899243-19-003277 · doc4.xml · derivative · entry 1 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,400 Underlying: Common Stock · 57,400 shares Expires 2029-02-07 F1 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments from January 1, 2019, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document
January 07, 2019 Filed Jan 9, 2019 21:21 UTC	MyoKardia, Inc. MYOK · Entity 145206	Tax withholdingCommon Stock	570	$42.98	$24,496.09	Disclosure SEC source: 0000899243-19-000901 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,755 Read SEC document
January 01, 2019 Filed Jan 3, 2019 21:38 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionRestricted Stock Units · Derivative	1,425	$0.00	$0.00	Disclosure SEC source: 0000899243-19-000374 · doc4.xml · derivative · entry 2 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,275 Underlying: Common Stock · 1,425 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document
January 01, 2019 Filed Jan 3, 2019 21:38 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionCommon Stock	1,425	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-000374 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
November 02, 2018 Filed Nov 6, 2018 19:30 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	978	$55.45	$54,230.10	Disclosure SEC source: 0000899243-18-028347 · doc4.xml · nonDerivative · entry 2 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,900 F2 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.